Follow-The-Filings

Security

CHRS

Coherus Biosciences Inc. · COM

Equity holders as of 2026 Q1 (each manager’s latest book)

7 owners 1 new max 0.0% (Vanguard Group Inc.)

grid → activity →
owners 7
max % 0.0%
tracked value $19M
qoq N 1 A 3 R 2

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Vanguard Group Inc. 2025 Q4 stale 0.0% Reduce 0.00 pp 10,028,893 $14M hist
Cliff Asness - Aqr Capital Management LLC 2026 Q1 0.0% Add 0.00 pp 1,206,046 $2M hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit 0.00 pp 503,875 $716 hist
Renaissance Technologies LLC 2026 Q1 0.0% Add 0.00 pp 331,700 $561 hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Reduce 0.00 pp 311,986 $527 hist
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% Add 0.00 pp 270,087 $456 hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% New 0.0% 233,946 $395 hist

7 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue — — —
Gross profit — — —
Gross margin — — —
Net income -$237.89M $28.51M $168.02M
Net margin — — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $475.63M $341.58M $206.71M
Total non-current assets * $153.97M $106.95M $51.64M
Total assets $629.6M $448.53M $258.34M
Total current liabilities $331.77M $282.98M $140.39M
Total non-current liabilities * $491.26M $297.54M $56.94M
Total equity -$193.42M -$131.99M $61.01M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$174.88M -$20.44M -$138.51M
Cash from investing $144.64M $230.32M $375.09M
Cash from financing $69.6M -$186.97M -$273.7M
Net change in cash $39.36M $22.91M -$37.13M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders